Abiraterone for treatment of germline mutation in BRCA1 gene with low age, high tumor burden and rapid progression of prostate cancer: a case report / 中华泌尿外科杂志
Chinese Journal of Urology
; (12): 27-29, 2021.
Article
ي Zh
| WPRIM
| ID: wpr-911169
المكتبة المسؤولة:
WPRO
ABSTRACT
The incidence of prostate cancer is increasing year by year in China. People with BRCA mutation are at high risk of prostate cancer. However, there is no clear and effective treatment for mHSPC with high metastatic load carrying BRCA mutation. In this study, we report a mHSPC patient with high metastatic burden and germline BRCA1 gene mutation who rapidly progressed to mCRPC after traditional CAB therapy and then received ADT combined with abiraterone and achieved significant PSA response, suggesting that ADT combined with abiraterone may be an effective therapy for mHSPC patients with BRCA1 germline mutation.
النص الكامل:
1
الفهرس:
WPRIM
اللغة:
Zh
مجلة:
Chinese Journal of Urology
السنة:
2021
نوع:
Article